HUE053949T2 - N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok - Google Patents

N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Info

Publication number
HUE053949T2
HUE053949T2 HUE10739701A HUE10739701A HUE053949T2 HU E053949 T2 HUE053949 T2 HU E053949T2 HU E10739701 A HUE10739701 A HU E10739701A HU E10739701 A HUE10739701 A HU E10739701A HU E053949 T2 HUE053949 T2 HU E053949T2
Authority
HU
Hungary
Prior art keywords
protofibrils
oligomers
terminally truncated
antibodies selective
truncated amyloid
Prior art date
Application number
HUE10739701A
Other languages
English (en)
Hungarian (hu)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda Soederberg
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of HUE053949T2 publication Critical patent/HUE053949T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE10739701A 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok HUE053949T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
HUE053949T2 true HUE053949T2 (hu) 2021-08-30

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10739701A HUE053949T2 (hu) 2009-06-29 2010-06-29 N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok

Country Status (16)

Country Link
US (2) US20120100129A1 (https=)
EP (2) EP2448968B1 (https=)
JP (3) JP2012532094A (https=)
AU (1) AU2010267640B2 (https=)
CA (1) CA2765602C (https=)
CY (1) CY1124034T1 (https=)
DK (1) DK2448968T3 (https=)
ES (1) ES2864049T3 (https=)
HR (1) HRP20210611T1 (https=)
HU (1) HUE053949T2 (https=)
LT (1) LT2448968T (https=)
PL (1) PL2448968T3 (https=)
PT (1) PT2448968T (https=)
SI (1) SI2448968T1 (https=)
SM (1) SMT202100237T1 (https=)
WO (1) WO2011001366A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
CA2828433C (en) 2011-03-16 2020-08-04 Probiodrug Ag Diagnostic antibody assay
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
WO2017013599A1 (en) 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
BR112019000098A2 (pt) 2016-07-14 2019-04-09 Bioarctic Ab proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US20210324056A1 (en) 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JPWO2021006212A1 (https=) * 2019-07-08 2021-01-14
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
DK4172199T3 (da) 2020-06-26 2025-08-18 Bioarctic Ab Alfa-synuklein-protofibril-bindende antistoffer
AU2022307687A1 (en) 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
US20240352109A1 (en) 2021-08-30 2024-10-24 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
DE60043165D1 (de) * 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
CA2414772C (en) * 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
EP2207568B1 (en) * 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína

Also Published As

Publication number Publication date
WO2011001366A1 (en) 2011-01-06
CA2765602A1 (en) 2011-01-06
AU2010267640A1 (en) 2012-01-19
JP2017197531A (ja) 2017-11-02
CA2765602C (en) 2021-05-25
EP2448968B1 (en) 2021-01-27
JP6884025B2 (ja) 2021-06-09
JP2012532094A (ja) 2012-12-13
HRP20210611T1 (hr) 2021-05-28
DK2448968T3 (da) 2021-04-12
JP2019218362A (ja) 2019-12-26
LT2448968T (lt) 2021-05-10
ES2864049T3 (es) 2021-10-13
AU2010267640B2 (en) 2015-03-05
EP3892633A1 (en) 2021-10-13
EP2448968A1 (en) 2012-05-09
US20230295283A1 (en) 2023-09-21
SI2448968T1 (sl) 2021-07-30
CY1124034T1 (el) 2022-05-27
PT2448968T (pt) 2021-04-30
PL2448968T3 (pl) 2021-09-13
US20120100129A1 (en) 2012-04-26
SMT202100237T1 (it) 2021-05-07

Similar Documents

Publication Publication Date Title
HUE053949T2 (hu) N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok
PT2406284T (pt) Anticorpos anti-bcma
EP2406399A4 (en) MIRAC PROTEINS
DOS2010000009S (es) Botella
DK2480734T3 (da) Skinnesystem
DOS2010000006S (es) Botella
EP2448809A4 (en) CHANNEL SYSTEM
UY3958Q (es) Botella
BRPI1008979A2 (pt) meio de fixação
ITPD20090053U1 (it) Paradordi per banchine
ES1071736Y (es) Botella
DE112010001522A5 (de) Mobile förderbrücke
DE112010001392A5 (de) Vibrator
ITCT20090003U1 (it) Telepass -2 per non udenti
TH93312B (th) ขวด
FR2951765B1 (fr) Paumelle pour persiennes
FI20090461A0 (fi) Määritysmenetelmä
FI20090460A0 (fi) Määritysmenetelmä
FI20096331A0 (fi) Antibodin käyttö
DOS2009000147S (es) Botella
DOS2009000212S (es) Botella
CR10687S (es) Viga bloque
TH93146B (th) ขวด
CN301360184S (zh)
UA19434S (uk) Пляшка